Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration with emtricitabine/tenofovir-DF alone has not been studied. No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 (metabolite of sofosbuvir), velpatasvir, voxilaprevir or emtricitabine was observed when sofosbuvir/velpatasvir/voxilaprevir was administered with various emtricitabine containing regimens. Sofosbuvir/velpatasvir/voxilaprevir has been shown to increase tenofovir exposure due to P-gp inhibition by velpatasvir and voxilaprevir. Tenofovir exposure (AUC and Cmax) increased by ~40% during co-treatment with sofosbuvir/velpatasvir/voxilaprevir and tenofovir-DF/emtricitabine (with darunavir/ritonavir). Patients receiving sofosbuvir/velpatasvir/voxilaprevir concomitantly with tenofovir-DF should be monitored for tenofovir associated adverse reactions.
Coadministration increases tenofovir concentrations. Coadministration of sofosbuvir/velpatasvir/voxilaprevir (400/100/100 mg once daily, plus 100 mg voxilaprevir) and tenofovir-DF (300 mg once daily) in the presence of darunavir/ritonavir increased tenofovir Cmax, AUC and Cmin by 48%, 39% and 47%, respectively (n=29). Monitor patients receiving Truvada concomitantly with Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for adverse reactions associated with TDF.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking